American Century Companies Inc. Has $2.42 Million Position in BioSpecifics Technologies Corp. (BSTC)

American Century Companies Inc. lifted its position in BioSpecifics Technologies Corp. (NASDAQ:BSTC) by 340.5% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 39,967 shares of the biopharmaceutical company’s stock after acquiring an additional 30,894 shares during the period. American Century Companies Inc.’s holdings in BioSpecifics Technologies were worth $2,422,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can bought a new position in shares of BioSpecifics Technologies in the fourth quarter valued at $54,000. Legal & General Group Plc grew its stake in shares of BioSpecifics Technologies by 50.1% in the fourth quarter. Legal & General Group Plc now owns 1,211 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 404 shares in the last quarter. Metropolitan Life Insurance Co. NY grew its stake in shares of BioSpecifics Technologies by 356.5% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 2,100 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 1,640 shares in the last quarter. Janus Henderson Group PLC bought a new position in shares of BioSpecifics Technologies in the third quarter valued at $225,000. Finally, MetLife Investment Advisors LLC bought a new position in shares of BioSpecifics Technologies in the third quarter valued at $273,000. 59.59% of the stock is owned by institutional investors and hedge funds.

BSTC stock opened at $67.11 on Tuesday. BioSpecifics Technologies Corp. has a one year low of $40.54 and a one year high of $73.31. The firm has a market cap of $488.09 million, a price-to-earnings ratio of 24.58 and a beta of 1.27.



BioSpecifics Technologies (NASDAQ:BSTC) last released its quarterly earnings data on Tuesday, April 2nd. The biopharmaceutical company reported $0.84 EPS for the quarter, topping the Zacks’ consensus estimate of $0.82 by $0.02. BioSpecifics Technologies had a net margin of 60.57% and a return on equity of 21.79%. The firm had revenue of $9.85 million during the quarter. On average, equities analysts predict that BioSpecifics Technologies Corp. will post 3.01 EPS for the current year.

A number of equities analysts have commented on the stock. HC Wainwright set a $85.00 price objective on shares of BioSpecifics Technologies and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Zacks Investment Research cut shares of BioSpecifics Technologies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 14th. Finally, BidaskClub cut shares of BioSpecifics Technologies from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 24th.

WARNING: “American Century Companies Inc. Has $2.42 Million Position in BioSpecifics Technologies Corp. (BSTC)” was published by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://dakotafinancialnews.com/2019/04/16/american-century-companies-inc-has-2-42-million-position-in-biospecifics-technologies-corp-bstc.html.

About BioSpecifics Technologies

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands.

See Also: Is the Dow Jones Industrial Average (DJIA) still relevant?

Want to see what other hedge funds are holding BSTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioSpecifics Technologies Corp. (NASDAQ:BSTC).

Institutional Ownership by Quarter for BioSpecifics Technologies (NASDAQ:BSTC)

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.